Abstract:Lung cancer patients with the epidermal growth factor receptor (EGFR) kinase domain mutations frequently show good responses to small molecule tyrosine kinase inhibitors, including Iressa and Tarceva, in clinical studies1, 2, 3. Previous studies have demonstrated that EGFR kinase domain mutations are commonly observed in lung adenocarcinomas, never-smokers, East Asian, and females4, 5, 6, 7, 8. In contrast to caucasion females, most East Asian females do not smoke, while tobacco smoking is very common in the male population. This gender-associated tobacco usage may bias the EGFR mutation incidence in lung adenocarcinoma patients. Here we analyzed the EGFR mutation rate together with gender and smoking status in Chinese lung adenocarcinoma patients. Interestingly, our results showed a comparable rate of EGFR kinase domain mutations in lung adenocarcinomas from Chinese male and female never-smokers. We have sequenced the EGFR kinase domain using cDNA extracted from 224 lung adenocarcinomas continuously collected from September 2007 to October 2009 at Shanghai Cancer Hospital, Fudan University, with patient consent. Clinical information including age, smoking history, stage and lung tumor differentiation status is listed in Table 1. All patients were Chinese; they came from Shanghai and 10 other provinces. About 62% (139/224) of the lung adenocarcinomas were from never-smokers, and about 38% (85/224) were from ever-smokers (Table 1). Only 2 of 110 Chinese females smoked, while 83 of 114 males were ever-smokers. About 63% (142/224) of lung adenocarcinomas harbored EGFR kinase domain mutations. Without considering gender-associated tobacco usage, our data were similar to those of previous reports4, 5. EGFR kinase domain mutations tended to occur in never-smokers (75.54%) more frequently than in ever-smokers (43.53%), and female patients had a higher mutation rate of the EGFR kinase domain (75.45%) than did male patients (51.75%) (P<0.01). We then analyzed the association of EGFR kinase domain mutations with gender in never-smokers and ever-smokers separately. About 55% (46/83) of male ever-smokers had EGFR mutations (Table 1). The only two female smokers had no EGFR mutations. Interestingly, a comparable EGFR kinase domain mutation rate was found in both male never-smokers (70.97%; 22/31) and female never-smokers (76.85%; 83/108) (Table 1). These data clearly showed that gender did not influence EGFR kinase domain mutation rates in never-smoker patients with lung adenocarcinomas. The low rate of EGFR mutations in males could possibly be ascribed to the low number/percentage of male never-smoker patients with lung adenocarcinomas. Similar conclusion has been drawn using Japanese clinical samples9, 10. Although Chinese and Japanese patients are both from East Asia, it has not been conclusively demonstrated that Japanese lung cancer patients are biologically the same as Chinese lung cancer patients. Our study using 224 lung adenocarcinoma specimens mainly from eastern China extends previous studies6, 7 and corroborates the notion that gender does not play a significant role in the distribution of EGFR mutations in lung adenocarcinoma. Further studies to include other areas in China and that significantly increase the patient number will be very helpful to solidify and extend our results. The status of EGFR kinase domain mutation has been proposed as one of most important factors used for Iressa or Tarceva treatment decision-making in clinic11. Based on our findings in this study, not only Chinese female never-smokers but also male never-smokers are likely to benefit from EGFR-targeted therapy. This work was supported by the National Basic Research Program of China (No 2010CB912102), the National Natural Science Foundation of China (No 30623003, 30740084, and 30871284), the Chinese Academy of Sciences (No 2008KIP101, KSCX1-YW-22), the Science and Technology Commission of Shanghai Municipality (No 08PJ14105, 09JC1416300) and the Hundred Talents Program of the Chinese Academy of Sciences to Prof Hong-bin JI.

Variation in the EGFR Gene is Associated with Lung Cancer

Mutation and Polymorphism in the EGFR-TK Domain Associated with Lung Cancer

Nucleotide Excision Repair Gene ERCC1 19007T>C Polymorphism Contributes to Lung Cancer Susceptibility: A Meta-Analysis

Hereditary Lung Cancer Syndrome Targets Never Smokers with Germline EGFR Gene T790M Mutations

[Clinicopathological Features Associated with EGFR Gene Mutation in Non-Small Cell Lung Cancer Patients].

EGFR Mutations in Patients with Lung Adenocarcinoma in Southwest China: Are G719S/A and L861Q More Likely Detected in Tumors Derived from Smokers?

Relationship Between Polymorphisms of DNA Repair Gene ERCC1 and Susceptibility to Lung Cancer

Association of EGFR Mutation or ALK Rearrangement with Expression of DNA Repair and Synthesis Genes in Never‐smoker Women with Pulmonary Adenocarcinoma

[Mutations in Exon 19 of EGFR Gene in Non-Small Cell Lung Cancer from Chinese Patients].

P1.01-85 the Prevalence of Different EGFR Exon20 Mutations in 12,833 Chinese Lung Cancer Patients

EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer

Comparable rate of EGFR kinase domain mutation in lung adenocarcinomas from Chinese male and female never-smokers

Egfr Exon 19 Insertions: A New Family of Sensitizing Egfr Mutations in Lung Adenocarcinoma

Diverse Responses to EGFR-TKIs in Patients with Concurrent Germline and Somatic EGFR Mutations

P2.03-12 EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer

[Relationship Between Mutations of Epidermal Growth Factor Receptor Gene and Clinicopathologic Features of Non-Small Cell Lung Cancers].

Better Survival with Epidermal Growth Factor Receptor Exon 19 Deletion Than with Exon 21 Mutation in Gefitinib-Treated Non-Small Cell Lung Cancer Patients is Due to Differential Inhibition of Downstream Signals

Mutation of Exon19 and Exon21 of epidermal growth factor receptor and clinical factor in nonsmall cell lung cancer

Abstract 6149: Polygenic risk score and lung adenocarcinoma risk among never-smokers by <i>EGFR</i> mutation status

-216G/T (rs712829), a Functional Variant of the EGFR Promoter, is Associated with the Pleural Metastasis of Lung Adenocarcinoma.

EGFR, ALK, RET, KRAS and BRAF Alterations in Never-Smokers with Non-Small Cell Lung Cancer.